Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530821 | 0.81 | ADORA3 (1.00) | ADORA3RXFP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27622288 | 0.80 | NPC1 (0.59) | NPC1RAB9APKMSMN1; SMN2TP53 | |
| SCHEMBL31110030 | 0.79 | NPC1 (0.55) | ADORA3RXFP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30911334 | 0.79 | ADORA3 (0.61) | ADORA3RXFP1NPC1RAB9APKM | |
| SCHEMBL3759738 | 0.79 | GRM1 (0.49) | ADORA3RXFP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5335555 | 0.77 | ALDH1A1 (0.53) | NPC1RAB9APKMSMN1; SMN2TP53 | |
| SCHEMBL8570794 | 0.77 | ADORA3 (0.62) | ADORA3RXFP1NPC1RAB9APKM | |
| SCHEMBL9852280 | 0.77 | ALDH1A1 (0.69) | RXFP1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL11220429 | 0.77 | ADORA3 (0.62) | ADORA3RXFP1NPC1RAB9APKM | |
| SCHEMBL31665226 | 0.77 | ALDH1A1 (0.51) | ADORA3RXFP1NPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4651714-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-20080312207-A1 | Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312207-A1 | Compounds | GRK4, PTGER4, GRK5 | ADORA3 1295/4885RXFP1 273/4885NPC1 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.